Blog
RSS FeedPosted by Michael Wonder on 17 Oct 2023
First treatment to be recommended by NICE at the same time it is approved for advanced lymphoma in the UK
17 October 2023 - More than 700 people set to benefit from new treatment option for advanced lymphoma. ...
Posted by Michael Wonder on 11 Oct 2023
Bimekizumab for the treatment of patients with axial spondyloarthritis
11 October 2023 - NICE has published final evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment ...
Posted by Michael Wonder on 04 Oct 2023
Bimekizumab for the treatment of patients with active psoriatic arthritis
4 October 2023 - NICE has recommended evidence based recommendations on the use of bimekizumab (Bimzelx) for the treatment of ...
Posted by Michael Wonder on 04 Oct 2023
Pegunigalsidase alfa for the treatment of patients with Fabry disease
4 October 2023 - NICE has published evidence-based recommendations on the use of pegunigalsidase alfa (Elfabrio) for the treatment of ...
Posted by Michael Wonder on 03 Oct 2023
Loncastuximab tesirine for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma and high-grade B-cell lymphoma after 2 or more systemic treatments
3 October 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 26 Sep 2023
NICE draft guidance recognises potential of new targeted treatment for type of advanced breast cancer
26 September 2023 - NICE has today published draft guidance for public consultation that does not recommend trastuzumab deruxtecan for ...
Posted by Michael Wonder on 24 Sep 2023
NICE recommends Lilly's mirikizumab (Omvoh) for the treatment of eligible adults with moderately to severely active ulcerative colitis
22 September 2023 - Eli Lilly announced today that NICE has recommended mirikizumab for the treatment of adults with moderately ...
Posted by Michael Wonder on 20 Sep 2023
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency
20 September 2023 - NICE has published evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adults with previously ...
Posted by Michael Wonder on 14 Sep 2023
First treatment for acute migraine to be recommended by NICE set to benefit thousands
14 September 2023 - The first treatment to be recommended by NICE for treating acute migraine will soon be available on ...
Posted by Michael Wonder on 08 Sep 2023
NICE committee recommends tirzepatide as new treatment option for people with type 2 diabetes
8 September 2023 - Around 180,000 people with difficult to manage type 2 diabetes could benefit from a new treatment ...
Posted by Michael Wonder on 06 Sep 2023
Mavacamten for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy
6 September 2023 - NICE has published final evidence-based recommendations on the use of mavacamten (Camzyos) for the treatment of ...
Posted by Michael Wonder on 05 Sep 2023
NICE recommends Chiesi’s Elfabrio for adults with Fabry disease
4 September 2023 - NICE has recommended Chiesi’s Elfabrio (pegunigalsidase alfa) as a long-term option for treating Fabry disease in ...
Posted by Michael Wonder on 18 Aug 2023
NICE draft guidance recommends novel treatment for debilitating inherited skin condition
18 August 2023 - Around 670 people in England with painful and debilitating skin wounds caused by a rare inherited disorder ...
Posted by Michael Wonder on 26 Jul 2023
Afamelanotide acetate for the treatment of patients with erythropoietic protoporphyria
27 July 2023 - NICE has published final evidence-based recommendations on the use of afamelanotide acetate (Scenesse) for the treatment ...
Posted by Michael Wonder on 26 Jul 2023
Selpercatinib for untreated RET fusion positive advanced non-small-cell lung cancer
26 July 2023 - NICE has published final evidence-based recommendations on the use of selpercatinib (Retsevmo) for adults with advanced, ...